The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06342-w ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Hematology, 2025. Verfasst von Chengxin Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Hematology, Southwest Hospital, Third Military Medical University, No. 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China. Hauptthemen laut MEDLINE: Decitabine, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing.
Abstract (Originalsprache)
Decitabine shows favorable efficacy in induction and maintenance therapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), but its role in pre-transplant conditioning still has not been established. We performed a systematic review and meta-analysis of comparative studies investigating the effects of adding decitabine to conditioning regimens in AML/MDS patients undergoing allogeneic hematopoietic stem cell transplantation. Meta-analysis was conducted with Review Manager 5.4. For time-to-event outcomes, pooled hazard ratios (HRs) were calculated using generic inverse-variance method. For dichotomous data, pooled risk ratios (RRs) were calculated using Mantel-Haenszel method. Fixed-effects model was adopted if there is no significant heterogeneity. Literature search and study selection identify 9 eligible studies, including 2 randomized controlled trials and 7 retrospective comparative studies. Meta-analysis show that addition of decitabine to conditioning regimen is associated with significantly better overall survival (HR 0.61; 95% CI: 0.49-0.76; P < 0.00001), reduced risk of relapse (HR 0.58; 95% CI: 0.46-0.73; P < 0.00001), and better disease-free survival (HR 0.67; 95% CI: 0.55-0.81; P < 0.0001) without increasing non-relapse mortality (HR 0.82; 95% CI: 0.56-1.18; P = 0.28) and grade II-IV acute graft-versus-host disease (RR 0.75; 95% CI: 0.54-1.04; P = 0.08).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Hematology, Southwest Hospital, Third Military Medical University, No. 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
- Key Laboratory of Cancer Immunotherapy of Chongqing, Chongqing, China.
- Department of Health Statistics, Third Military Medical University, Chongqing, China.
- Department of Hematology, Daping Hospital, Third Military Medical University, No. 10 Chang-Jiang Brunch Road, Yuzhong district, Chongqing, 400042, China. lixi1988xn@163.com.
- Center for Hematology, Southwest Hospital, Third Military Medical University, No. 30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China. xushuangnian@tmmu.edu.cn.
- Department of Health Statistics, Third Military Medical University, Chongqing, China. xushuangnian@tmmu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
Zitieren
APA
Luo, C., Zhang, J., Huang, X., Wu, G., Huang, Y., Ding, Y., Huang, Z., Song, Q., Chen, J., Li, X., & Xu, S. (2025). The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Annals of Hematology. https://doi.org/10.1007/s00277-025-06342-w
Vancouver
Luo C, Zhang J, Huang X, Wu G, Huang Y, Ding Y, et al. The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Annals of Hematology. 2025. doi:10.1007/s00277-025-06342-w
BibTeX
@article{Luo2025,
author = {Luo, Chengxin and Zhang, Jianmin and Huang, Xiangtao and Wu, Guixian and Huang, Yarui and Ding, Yaqun and Huang, Zhen and Song, Qiuyue and Chen, Jieping and Li, Xi and Xu, Shuangnian},
title = {The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06342-w}
}
EUVIMED